UK’s NICE recommends Novartis’ Afinitor to treat neuroendocrine tumours
The recommendation covers the drug as therapy for NETs that are well- or moderately-differentiated, unresectable or metastatic, and of pancreatic origin in patients with progressive disease. Afinitor has
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.